Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIM1 | P11309 | 3/20 | 0.52 |
| ▸ | RXRA | P19793 | 6/20 | 0.45 |
| ▸ | GRIN1 | Q05586 | 6/20 | 0.45 |
| ▸ | GRIN2B | Q13224 | 6/20 | 0.45 |
| ▸ | HTR2C | P28335 | 3/20 | 0.44 |
| ▸ | HTR2A | P28223 | 2/20 | 0.44 |
| ▸ | HTR2B | P41595 | 2/20 | 0.44 |
| ▸ | TACR1 | P25103 | 1/20 | 0.44 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.44 |
| ▸ | ADRB1 | P08588 | 2/20 | 0.43 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.43 |
| ▸ | HTR1A | P08908 | 1/20 | 0.43 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.43 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.43 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.43 |
| ▸ | FPR3 | P25089 | 1/20 | 0.43 |
| ▸ | HTR1D | P28221 | 1/20 | 0.43 |
| ▸ | HTR1B | P28222 | 1/20 | 0.43 |
| ▸ | HTR1E | P28566 | 1/20 | 0.43 |
| ▸ | GPR183 | P32249 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL906199 | 0.87 | HTR6 (0.51) | HTR2CHTR2AHTR2BPRMT5ADRB1 | |
| SCHEMBL905954 | 0.86 | KDM4E (0.51) | PIM1HTR2CHTR2AHTR2BPRMT5 | |
| SCHEMBL5585277 | 0.85 | ADRB1 (0.54) | RXRAGRIN1GRIN2BHTR2CHTR2A | |
| SCHEMBL5585318 | 0.85 | HTR2A (0.45) | PIM1HTR2CHTR2AHTR2BPRMT5 | |
| SCHEMBL906110 | 0.84 | PRMT5 (0.56) | RXRAGRIN1GRIN2BHTR2CHTR2A | |
| SCHEMBL906027 | 0.81 | HTR2C (0.64) | HTR2CHTR2AHTR2BADRB1CHRM4 | |
| SCHEMBL906132 | 0.81 | HTR1A (0.53) | PIM1HTR2CHTR2AHTR2BPRMT5 | |
| SCHEMBL5585635 | 0.80 | HTR3A (0.48) | PIM1HTR2CHTR2AHTR2BPRMT5 | |
| SCHEMBL905995 | 0.78 | HRH3 (0.48) | RXRAGRIN1GRIN2BHTR2CHTR2A | |
| SCHEMBL905754 | 0.75 | HTR2C (0.50) | HTR2CHTR2AHTR2BTACR1ADRB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7247633-B2 | Pyrimidine compounds and their use | BIOVITRUM AB (SE) | 2007-07-24 | — | — | US | disclosed |
| US-20040014767-A1 | Novel compounds and their use | BIOVITRUM AB, A SWEDISH CORPORATION | 2004-01-22 | — | — | US | disclosed |
| EP-1335907-A1 | PIPERAZINYLPYRAZINE COMPOUNDS AS AGONIST OR ANTAGONIST OF SEROTONIN 5HT-2 RECEPTOR | BIOVITRUM AB (SE) | 2003-08-20 | — | — | EP | disclosed |
| US-6593330-B2 | Central nervous system disorders; antiserotonine agents | BIOVITRUM (SE) | 2003-07-15 | — | — | US | disclosed |
| US-20020147200-A1 | Novel compounds and their use | PROXIMAGEN NEUROSCIENCE PLC (GB) | 2002-10-10 | — | — | US | disclosed |
| WO-2002040456-A1 | PIPERAZINYLPYRAZINE COMPOUNDS AS AGONIST OR ANTAGONIST OF SEROTONIN 5HT-2 RECEPTOR | BIOVITRUM AB (SE) | 2002-05-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020147200-A1 | Novel compounds and their use | BRIX1, UGT1A1, NR5A1 | PIM1 2536/4885RXRA 48/4885GRIN1 253/4885 |
| US-20040014767-A1 | Novel compounds and their use | BRIX1, UGT1A1, NR5A1 | PIM1 2536/4885RXRA 48/4885GRIN1 253/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.